Literature DB >> 2876571

Hyperthyroidism due to non-tumoural inappropriate TSH secretion. Effect of a long-acting somatostatin analogue (SMS 201-995).

G Williams, M Kraenzlin, L Sandler, J Burrin, A Law, S Bloom, G F Joplin.   

Abstract

Inappropriate hypersecretion of TSH was investigated in a 25 year old man whose hyperthyroidism had relapsed 4 years after subtotal thyroidectomy. Serum TSH levels were further increased by both TRH and metoclopramide and were partially suppressed by triiodothyronine (120 micrograms/day). The serum alpha-subunit: TSH molar ratio was less than 1.0, and computerised axial tomography showed no evidence of a pituitary tumour. These features are characteristic of inappropriate TSH secretion due to thyrotroph resistance to thyroid hormones. A long-acting somatostatin analogue (SMS 201-995), 50 micrograms injected sc twice-daily for three days, suppressed TSH levels and nearly normalised thyroid hormone levels. Somatostatin analogues may be therapeutically useful in thyrotoxicosis due to non-tumoural inappropriate TSH hypersecretion.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2876571

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  4 in total

1.  Clinical hyperthyroidism due to non-neoplastic inappropriate thyrotrophin secretion.

Authors:  A W Chan; I A MacFarlane; C van Heyningen; P M Foy
Journal:  Postgrad Med J       Date:  1990-09       Impact factor: 2.401

2.  Clinical use of the somatostatin analog SMS 201-995 in endocrinology.

Authors:  R Cozzi; A Liuzzi; D Dallabonzana; G Oppizzi; P Orlandi; C De Palo; M M Petroncini; M Piolini; P G Chiodini
Journal:  J Endocrinol Invest       Date:  1988-11       Impact factor: 4.256

3.  Genetic analysis of 29 kindreds with generalized and pituitary resistance to thyroid hormone. Identification of thirteen novel mutations in the thyroid hormone receptor beta gene.

Authors:  M Adams; C Matthews; T N Collingwood; Y Tone; P Beck-Peccoz; K K Chatterjee
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

Review 4.  Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion.

Authors:  P E Battershill; S P Clissold
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.